Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Highlights on selpercatinib in RET fusion-positive NSCLC: The LIBRETTO-431 study

Dr Herbert Ho Fung Loong reports on key results from ESMO Congress 2023 on the LIBRETTO-431 study

LBA4 - Randomized Phase 3 Study of First-line Selpercatinib versus Chemotherapy and Pembrolizumab in RET Fusion-positive NSCLC

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.